Literature DB >> 24787006

miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1.

Marek Mraz1, Liguang Chen2, Laura Z Rassenti2, Emanuela M Ghia2, Hongying Li2, Kristen Jepsen2, Erin N Smith2, Karen Messer2, Kelly A Frazer2, Thomas J Kipps2.   

Abstract

We examined the microRNAs (miRNAs) expressed in chronic lymphocytic leukemia (CLL) and identified miR-150 as the most abundant, but with leukemia cell expression levels that varied among patients. CLL cells that expressed ζ-chain-associated protein of 70 kDa (ZAP-70) or that used unmutated immunoglobulin heavy chain variable (IGHV) genes, each had a median expression level of miR-150 that was significantly lower than that of ZAP-70-negative CLL cells or those that used mutated IGHV genes. In samples stratified for expression of miR-150, CLL cells with low-level miR-150 expressed relatively higher levels of forkhead box P1 (FOXP1) and GRB2-associated binding protein 1 (GAB1), genes with 3' untranslated regions having evolutionary-conserved binding sites for miR-150. High-level expression of miR-150 could repress expression of these genes, which encode proteins that enhance B-cell receptor signaling, a putative CLL-growth/survival signal. Also, high-level expression of miR-150 was a significant independent predictor of longer treatment-free survival or overall survival, whereas an inverse association was observed for high-level expression of GAB1 or FOXP1 for overall survival. This study demonstrates that expression of miR-150 can influence the relative expression of GAB1 and FOXP1 and the signaling potential of the B-cell receptor, thereby possibly accounting for the noted association of expression of miR-150 and disease outcome.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24787006      PMCID: PMC4125356          DOI: 10.1182/blood-2013-09-527234

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  65 in total

1.  The Gab1 docking protein links the b cell antigen receptor to the phosphatidylinositol 3-kinase/Akt signaling pathway and to the SHP2 tyrosine phosphatase.

Authors:  R J Ingham; L Santos; M Dang-Lawson; M Holgado-Madruga; P Dudek; C R Maroun; A J Wong; L Matsuuchi; M R Gold
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

2.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Lang Huynh; Tracy L Toy; Liguang Chen; Michael J Keating; John G Gribben; Donna S Neuberg; Ian W Flinn; Kanti R Rai; John C Byrd; Neil E Kay; Andrew Greaves; Arthur Weiss; Thomas J Kipps
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

3.  Foxp1 is an essential transcriptional regulator of B cell development.

Authors:  Hui Hu; Bin Wang; Madhuri Borde; Julie Nardone; Shan Maika; Laura Allred; Philip W Tucker; Anjana Rao
Journal:  Nat Immunol       Date:  2006-07-02       Impact factor: 25.606

4.  CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis.

Authors:  S Zupo; L Isnardi; M Megna; R Massara; F Malavasi; M Dono; E Cosulich; M Ferrarini
Journal:  Blood       Date:  1996-08-15       Impact factor: 22.113

5.  Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.

Authors:  Yuri Pekarsky; Urmila Santanam; Amelia Cimmino; Alexey Palamarchuk; Alexey Efanov; Vadim Maximov; Stefano Volinia; Hansjuerg Alder; Chang-Gong Liu; Laura Rassenti; George A Calin; John P Hagan; Thomas Kipps; Carlo M Croce
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

6.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Calin Dan Dumitru; Masayoshi Shimizu; Roberta Bichi; Simona Zupo; Evan Noch; Hansjuerg Aldler; Sashi Rattan; Michael Keating; Kanti Rai; Laura Rassenti; Thomas Kipps; Massimo Negrini; Florencia Bullrich; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

7.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

8.  Independent regulation of c-myc, B-myb, and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes.

Authors:  J Golay; G Cusmano; M Introna
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

9.  Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.

Authors:  Sharon L Barrans; James A L Fenton; Alison Banham; Roger G Owen; Andrew S Jack
Journal:  Blood       Date:  2004-07-06       Impact factor: 22.113

10.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Liguang Chen; George Widhopf; Lang Huynh; Laura Rassenti; Kanti R Rai; Arthur Weiss; Thomas J Kipps
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

View more
  63 in total

1.  Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.

Authors:  Beverly A Teicher; Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Anne Monks; Joel Morris
Journal:  Mol Cancer Ther       Date:  2015-09-08       Impact factor: 6.261

2.  Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

Authors:  Yuh-Ying Yeh; Hatice Gulcin Ozer; Amy M Lehman; Kami Maddocks; Lianbo Yu; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

3.  p53-dependent non-coding RNA networks in chronic lymphocytic leukemia.

Authors:  C J Blume; A Hotz-Wagenblatt; J Hüllein; L Sellner; A Jethwa; T Stolz; M Slabicki; K Lee; A Sharathchandra; A Benner; S Dietrich; C C Oakes; P Dreger; D te Raa; A P Kater; A Jauch; O Merkel; M Oren; T Hielscher; T Zenz
Journal:  Leukemia       Date:  2015-05-14       Impact factor: 11.528

Review 4.  MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.

Authors:  K Musilova; M Mraz
Journal:  Leukemia       Date:  2014-12-26       Impact factor: 11.528

Review 5.  MicroRNA regulation of lymphocyte tolerance and autoimmunity.

Authors:  Laura J Simpson; K Mark Ansel
Journal:  J Clin Invest       Date:  2015-06-01       Impact factor: 14.808

6.  Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia.

Authors:  Basile Stamatopoulos; Michaël Van Damme; Emerence Crompot; Barbara Dessars; Hakim El Housni; Philippe Mineur; Nathalie Meuleman; Dominique Bron; Laurence Lagneaux
Journal:  Mol Med       Date:  2015-01-09       Impact factor: 6.354

7.  Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.

Authors:  Gabriela Pavlasova; Marek Borsky; Vaclav Seda; Katerina Cerna; Jitka Osickova; Michael Doubek; Jiri Mayer; Raffaele Calogero; Martin Trbusek; Sarka Pospisilova; Matthew S Davids; Thomas J Kipps; Jennifer R Brown; Marek Mraz
Journal:  Blood       Date:  2016-08-01       Impact factor: 22.113

8.  FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Authors:  Anja Mottok; Vindi Jurinovic; Pedro Farinha; Andreas Rosenwald; Ellen Leich; German Ott; Heike Horn; Wolfram Klapper; Michael Boesl; Wolfgang Hiddemann; Christian Steidl; Joseph M Connors; Laurie H Sehn; Randy D Gascoyne; Eva Hoster; Oliver Weigert; Robert Kridel
Journal:  Blood       Date:  2017-11-09       Impact factor: 22.113

Review 9.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

Review 10.  MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?

Authors:  Katrien Van Roosbroeck; George A Calin
Journal:  Semin Oncol       Date:  2016-02-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.